Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933742 | 0.97 | — | — | |
| SCHEMBL7942675 | 0.84 | — | — | |
| SCHEMBL8137257 | 0.78 | TP53 (0.36) | — | |
| SCHEMBL11702171 | 0.78 | CYP1A2 (0.37) | CYP1A2CTSK | |
| SCHEMBL16934238 | 0.76 | TP53 (0.32) | CHRM5CYP1A2ADRA2CCHRM2CHRM4 | |
| SCHEMBL11700253 | 0.76 | EPHX1 (0.37) | CYP1A2EPHX1 | |
| SCHEMBL11700781 | 0.76 | EPHX1 (0.37) | CYP1A2EPHX1 | |
| SCHEMBL11813116 | 0.74 | — | — | |
| SCHEMBL11743504 | 0.74 | SHBG (0.41) | CYP1A2DPP4CTSK | |
| SCHEMBL4201257 | 0.72 | CTSK (0.33) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| EP-3527600-B1 | ISOCYANATE COMPOSITION AND PRODUCTION METHOD FOR ISOCYANATE POLYMER | ASAHI CHEMICAL IND (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-01-10 | — | — | US | disclosed |
| CN-109803992-B | Isocyanate composition and method for producing isocyanate polymer | 旭化成株式会社 | 2022-05-24 | — | — | CN | disclosed |
| CN-109843963-B | Isocyanate composition, method for producing isocyanate polymer, and isocyanate polymer | 旭化成株式会社 | 2022-05-13 | — | — | CN | disclosed |
| EP-3536683-B1 | POLYISOCYANATE COMPOSITION AND ISOCYANATE POLYMER COMPOSITION | ASAHI CHEMICAL IND (JP) | 2021-11-24 | — | — | EP | disclosed |
| US-11174337-B2 | Isocyanate composition, method for producing isocyanate polymer and isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-11-16 | — | — | US | disclosed |
| CN-107963982-B | Polyisocyanate composition and isocyanate polymer composition | 旭化成株式会社 | 2021-11-12 | — | — | CN | disclosed |
| EP-3372579-B1 | POLYISOCYANATE COMPOSITION AND ISOCYANATE POLYMER COMPOSITION | ASAHI CHEMICAL IND (JP) | 2020-10-28 | — | — | EP | disclosed |
| EP-2097408-A1 | IMPROVED PROCESS FOR EPROSARTAN | Hetero Drugs Limited (IN) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008078330-A1 | IMPROVED PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2008-07-03 | — | — | WO | disclosed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| EP-0970073-B1 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORP (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-0970073-A4 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORP (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6172237-B1 | Process for preparing eprosartan | SMITHKLINE BEECHAM CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0970073-A1 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORPORATION (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035963-A1 | PROCESS FOR PREPARING EPROSARTAN | SMITHKLINE BEECHAM CORPORATION (US) | 1998-08-20 | — | — | WO | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | CHRM5 2336/4885CYP1A2 214/4885ADRA2C 2048/4885 |
| US-11548975-B2 | Isocyanate composition and method for producing isocyanate polymer | IDH3A, IDH2, IDH3B | CHRM5 3418/4885CYP1A2 195/4885ADRA2C 4639/4885 |
| US-20230114799-A1 | ISOCYANATE COMPOSITION AND METHOD FOR PRODUCING ISOCYANATE POLYMER | IDH3A, IDH2, IDH3B | CHRM5 3513/4885CYP1A2 183/4885ADRA2C 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.